Codiak BioSciences Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.0091
- Today's High:
- $0.0121
- Open Price:
- $0.0106
- 52W Low:
- $0.008
- 52W High:
- $4.25
- Prev. Close:
- $0.0131
- Volume:
- 96692
Company Statistics
- Market Cap.:
- $2.83 million
- Book Value:
- 1.057
- Revenue TTM:
- $34.07 million
- Operating Margin TTM:
- -154.41%
- Gross Profit TTM:
- $-41920000
- Profit Margin:
- -51.13%
- Return on Assets TTM:
- -22.43%
- Return on Equity TTM:
- -47.77%
Company Profile
Codiak BioSciences Inc had its IPO on 2020-10-14 under the ticker symbol CDAK.
The company operates in the Healthcare sector and Biotechnology industry. Codiak BioSciences Inc has a staff strength of 102 employees.
Stock update
Shares of Codiak BioSciences Inc opened at $0.01 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.01 - $0.01, and closed at $0.01.
This is a -7.63% slip from the previous day's closing price.
A total volume of 96,692 shares were traded at the close of the day’s session.
In the last one week, shares of Codiak BioSciences Inc have increased by +10%.
Codiak BioSciences Inc's Key Ratios
Codiak BioSciences Inc has a market cap of $2.83 million, indicating a price to book ratio of 0.5483 and a price to sales ratio of 0.5943.
In the last 12-months Codiak BioSciences Inc’s revenue was $34.07 million with a gross profit of $-41920000 and an EBITDA of $-48287000. The EBITDA ratio measures Codiak BioSciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Codiak BioSciences Inc’s operating margin was -154.41% while its return on assets stood at -22.43% with a return of equity of -47.77%.
In Q3, Codiak BioSciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 54.9%.
Codiak BioSciences Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.46 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Codiak BioSciences Inc’s profitability.
Codiak BioSciences Inc stock is trading at a EV to sales ratio of 0.9192 and a EV to EBITDA ratio of -3.2796. Its price to sales ratio in the trailing 12-months stood at 0.5943.
Codiak BioSciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $134.40 million
- Total Liabilities
- $14.46 million
- Operating Cash Flow
- $-9000.00
- Capital Expenditure
- $9000
- Dividend Payout Ratio
- 0%
Codiak BioSciences Inc ended 2024 with $134.40 million in total assets and $0 in total liabilities. Its intangible assets were valued at $134.40 million while shareholder equity stood at $38.93 million.
Codiak BioSciences Inc ended 2024 with $0 in deferred long-term liabilities, $14.46 million in other current liabilities, 4000.00 in common stock, $-359328000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $51.76 million and cash and short-term investments were $51.76 million. The company’s total short-term debt was $3,011,000 while long-term debt stood at $25.69 million.
Codiak BioSciences Inc’s total current assets stands at $61.23 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.96 million and inventory worth $0.
In 2024, Codiak BioSciences Inc's operating cash flow was $-9000.00 while its capital expenditure stood at $9000.
Comparatively, Codiak BioSciences Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.01
- 52-Week High
- $4.25
- 52-Week Low
- $0.008
- Analyst Target Price
- $5.8
Codiak BioSciences Inc stock is currently trading at $0.01 per share. It touched a 52-week high of $4.25 and a 52-week low of $4.25. Analysts tracking the stock have a 12-month average target price of $5.8.
Its 50-day moving average was $0.04 and 200-day moving average was $0.61 The short ratio stood at 2.23 indicating a short percent outstanding of 0%.
Around 47.7% of the company’s stock are held by insiders while 7152.5% are held by institutions.
Frequently Asked Questions About Codiak BioSciences Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. On March 27, 2023, Codiak BioSciences, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.